This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Should We Keep Calling Antidepressants Antidepressants?

Article Abstract

Letter to the Editor

Sir: In his recent comprehensive review "New Indications for Antidepressants," Schatzberg finely points out the therapeutic efficacy of serotonin reuptake inhibitors, nefazodone, venlafaxine, mirtazapine, and bupropion for a wide range of disorders beyond major depression, such as generalized anxiety disorder, obsessive-compulsive disorder (OCD), social phobia, panic disorder, posttraumatic stress disorder, bulimia nervosa, aggressive behavior, and nicotine dependence, not to mention the efficacy of some so-called antidepressant drugs in migraine, chronic pain, and attention-deficit/hyperactivity disorder. Moreover, a few studies suggest that improvement of certain specific endpoints was independent of changes in depression. So, why keep calling these drugs antidepressants?


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 62

Quick Links: Depression (MDD)